RDY Stock Recent News
RDY LATEST HEADLINES
Doctor Reddy's (RDY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
In the ever-evolving financial markets, savvy investors are always on the lookout for golden opportunities that offer great value. While the headlines often spotlight stocks that are soaring to new heights, some of the best investment prospects lie in stocks trading below their historical valuations.
Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes.
Caterpillar (CAT), KB Home (KBH), Walmart (WMT), Dr. Reddy's (RDY) and FedEx (FDX) could be solid choices amid the current market volatility.
Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes.
Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Trip.com (TCOM), Dr. Reddy's (RDY), Sterling Check (STER) and MINISO Group (MNSO) are poised to gain.
Dr. Reddy's (RDY) reports better-than-expected fiscal first-quarter 2024 results.
Dr. Reddy's Laboratories Ltd. (RDY) remains an attractive investment due to its strong Q4 and FY'23 numbers, exposure to the Indian generics market, and consistent new product launches. RDY is well-positioned in the high-growth generics market, along with other favorable business economics. Findings suggest RDY stock could be a buy with a target price of $60/share.
Dr. Reddy's (RDY) announces meeting primary and secondary endpoints in the phase I study of its proposed tocilizumab biosimilar for the treatment of rheumatoid arthritis in adults.